Moderna Update - Search News

Agrees to review Moderna flu vaccine

FDA reverses course, will review Moderna's mRNA flu vaccine

Moderna said on Wednesday the U.S. Food and Drug Administration has agreed to review its influenza vaccine, reversing an earlier decision to reject the application, after the company made modification...

· 1d · on MSN

Moderna says FDA to review its flu vaccine after reversing course

Straight Arrow News (English) on MSN · 1d

FDA to review Moderna's mRNA flu vaccine after initial rejection

· 1d

FDA Reverses Course, Will Review Moderna's mRNA Flu Vaccine

Moderna said the U.S. Food and Drug Administration has agreed to review its influenza vaccine, reversing an earlier decision to reject the application.

· 22h

FDA reverses course on Moderna's flu vaccine

Scientific American · 1d

FDA agrees to review Moderna mRNA flu vaccine in dramatic reversal

· 1d

FDA Reverses Course and Will Now Review Moderna’s Flu Shot

The move means that Moderna’s experimental flu shot is largely back on track after the FDA’s surprise decision earlier this month to refuse to start a review of its application.

Axios · 1d

FDA will now review flu vaccine it had rejected

· 1d

US FDA reverses course, will review Moderna's flu vaccine application

BioSpace

Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

BioNTech sues Moderna for patent infringement over COVID shots

German biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNEXSPIKE infringes a patent related to BioNTech and Pfizer's competing shot Comirnaty.

16h

Moderna to Present at Upcoming Conferences in March 2026

Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: